Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)

Cannot have received: systemic anti-lymphoma therapy

Exception: H. pylori eradication therapy in H. pylori-positive gastric MALT patients

No prior systemic anti-lymphoma therapy (except for H. pylori eradication therapy in H. pylori-positive gastric MALT patients)

Cannot have received: BTK inhibitor

Patients who have previously used BTK inhibitors

Cannot have received: CD20 monoclonal antibody therapy

Patients who have previously...received CD20 monoclonal antibody therapy

Cannot have received: allogeneic hematopoietic stem cell transplantation

Patients who have undergone allogeneic hematopoietic stem cell transplantation in the past

Cannot have received: anti-tumor therapy

Patients who have received anti-tumor therapy within 4 weeks prior to enrollment

Cannot have received: systemic corticosteroid

Patients who have received systemic corticosteroid treatment or other immunosuppressive therapy within 14 days prior to the start of study treatment

Cannot have received: immunosuppressive therapy

Patients who have received systemic corticosteroid treatment or other immunosuppressive therapy within 14 days prior to the start of study treatment